|
J&J Abiraterone going generic
|
4
|
Zenith Epigenetics
|
Nov 21, 2018 02:31PM
|
|
Re: J&J Abiraterone going generic
|
2
|
Zenith Epigenetics
|
Nov 21, 2018 03:48PM
|
|
Re: Losing exclusivity on Aberatirone may not be all that bad for JNJ or ZEL
|
6
|
Zenith Epigenetics
|
Nov 22, 2018 01:42PM
|
|
Re: What is Mr. Market saying about RVX?
|
|
Resverlogix Corp.
|
Nov 25, 2018 11:27PM
|
|
Mace Events Study / Type 2 Diabetes / Control Arms 26 CVOT Trials
|
2
|
Resverlogix Corp.
|
Nov 28, 2018 12:50PM
|
|
Tundup
|
1
|
Resverlogix Corp.
|
Nov 30, 2018 10:13AM
|
|
Re: Tundup
|
1
|
Resverlogix Corp.
|
Nov 30, 2018 10:53AM
|
|
Re: Are statins overprescribed? Why the risks and benefits are so complex / Pitavastatin
|
3
|
Resverlogix Corp.
|
Dec 04, 2018 08:37PM
|
|
Re: Are statins overprescribed? Why the risks and benefits are so complex / Pitavastatin
|
2
|
Resverlogix Corp.
|
Dec 04, 2018 09:19PM
|
|
Re: NASH is a $35 Billion US/year market
|
1
|
Resverlogix Corp.
|
Dec 31, 2018 07:21PM
|
|
Re: NASH is a $35 Billion US/year market
|
2
|
Resverlogix Corp.
|
Dec 31, 2018 09:38PM
|
|
ZE Slides Up
|
6
|
Zenith Epigenetics
|
Jan 08, 2019 03:58PM
|
|
Re: New article on BET Inhibitors in Cardiovascular Disease
|
6
|
Resverlogix Corp.
|
Jan 30, 2019 01:30PM
|
|
Re: Contest Tally
|
1
|
Resverlogix Corp.
|
Feb 14, 2019 01:20AM
|
|
Re: BETonMACE Placebo Estimate
|
3
|
Resverlogix Corp.
|
Feb 20, 2019 09:53AM
|
|
Re: BETonMACE Placebo Estimate
|
1
|
Resverlogix Corp.
|
Feb 20, 2019 05:44PM
|
|
Re: BETonMACE Placebo Estimate
|
2
|
Resverlogix Corp.
|
Feb 20, 2019 06:11PM
|
|
Prostate Ca / Brd4
|
4
|
Zenith Epigenetics
|
Feb 21, 2019 09:49AM
|
|
Re: Question about Phase 2
|
3
|
Resverlogix Corp.
|
Mar 12, 2019 09:50AM
|
|
Re: Kudos to Dr. Kausik Ray
|
1
|
Resverlogix Corp.
|
Mar 13, 2019 07:36PM
|
